Anticoagulant effects of Edoxiaban and those inhibitors in patients with venous thromboembolism.
Not Applicable
- Conditions
- Venous thromboembolism (VTE)
- Registration Number
- JPRN-UMIN000041973
- Lead Sponsor
- Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 243
Inclusion Criteria
Not provided
Exclusion Criteria
Patients under 20 years-old. Patients with hemodynamically insufficiency. Patients who need thrombolytic therapy or emergent thrombectomy. Terminal cancer patients those life prognosis are less than 3 months. Patients taking Edoxaban, unfractionated heparin or fondaparinux before VTE diagnosis.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method PT, APTT and D-dimer value after Edoxaban administration.
- Secondary Outcome Measures
Name Time Method Compare delta PT and delta APTT (difference in PT or APTT value before and 5 hours after Edoxaban administration) in cancer and non-cancer patients. Identify the time when D-dimer decrease below 50% of baseline value. Compare changes of D-dimer value after Edoxaban administration in cancer and non-cancer patients. Identify factors those inhibit PT and APTT prolongation by Edoxaban administration. Identify factors those inhibit D-dimer decrease by Edoxaban administration. Assess recurrent VTE, interruption of Edoxaban administration, major bleeding events, clinically relevant non-major bleeding events and death.